Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib vs Docetaxel/Cisplatin in EGFR+ Lung Adenocarcinoma
NCT01131429Phase 2Unknown
- Sponsor
- Chinese PLA General Hospital
- Start
- Jun 2010
- Primary completion
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of erlotinib in lung adenocarcinoma (LUAD), sponsored by Chinese PLA General Hospital. Primary endpoint: Overall Survival at 3 years. Status: unknown.
02
Drugs
erlotinib
03
Conditions
lung adenocarcinoma (LUAD)
Beyond the preview
Go deeper on NCT01131429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01131429.